Despite Efforts, Frequency of ‘Same Day’ Teaching Was Unchanged With Chemotherapy Education Policy

Article

A new Chemotherapy Education Policy at an NCCN-designated oncology center was received well by nursing and pharmacy staff, yet failed to meet its goals of better-informing patients about their therapy prior to their first dose.

Despite good reception by staff, a new chemotherapy education policy that mandates pre-treatment patient education and defines standards for the process did not meet its goals of increasing the quality of or decreasing instances of patient education, according to a poster presentation at the Oncology Nursing Society’s 46th Annual Congress.

Although nursing and pharmacy staff responded positively to a new Chemotherapy Education Policy mandating pre-treatment patient education and defining standards for the process, it failed to meet its goals of increasing the quality of that education and decreasing the instances of patients receiving education on the day of their first dose, according to a poster presentation at this year’s Oncology Nursing Society Annual Congress.

The researchers aimed to standardize and increase the quality of the pre-treatment chemotherapy education process and to decrease the amount of patients receiving “same day chemo teaches,” or learning about their treatment on the day of their first dose, to reduce patient anxiety and increase understanding.

“At our National Comprehensive Cancer Network (NCCN)-designated ambulatory oncology center, patients are educated about their treatment by both nurses and pharmacists,” said Martha Read, MSN, RN, OCN, of the Seattle Cancer Care Alliance, during the presentation. “There was a lack of consistency in the educational content covered, the materials that were given to the patient and when the education took place.”

To reach these goals, a chemotherapy education committee comprised of providers, pharmacists, nurses, supportive care and patient education services developed a policy to standardize the education process, with identified benchmarks. These changes defined standards for educational materials and acceptable online resources, educational content (common side effects, treatment schedule, supportive care, when to contact team), documentation and education scheduling of pre-treatment and a 3-day post-treatment follow up call from the clinic nurse.

After implementing the new education policy, the percentage of patients receiving chemotherapy education on the same day as their first day of treatment dropped from 33% to 28%. While the number went down, and nursing and pharmacy staff responded positively to the changes, Read explained, post-intervention, “same day chemo” teaches still happened between 41-48% of the time.

“Our next steps are to identify the barriers to providing pre-treatment chemotherapy education prior to the first day of treatment,” said Read. “And also, to provide additional education to reinforce the standards that were set in our policy.”

The researchers also plan to evaluate the implementation of the three-day follow up call obtaining patient feedback on the education experience.

Reference

Read M. Improving Chemotherapy Patient Education through Standardization: Does a Policy Help? Presented at: Oncology Nursing Society 46th Annual Congress; April 20, 22, 27, and 29, 2021. ePoster 1536. https://ons.confex.com/ons/2021/cp/eposterview.cgi?eposterid=1536

Recent Videos
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Using bispecific antibodies before or after CAR T-cell therapy in multiple myeloma is an area of education for community oncologists.
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
Optimal cancer survivorship care may entail collaboration between a treating oncologist and a cancer survivorship expert.
Related Content